Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

SAN DIEGO & CAMBRIDGE, England–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical company based in France, to jointly identify and enable new therapeutic targets. The new three-year research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as part of the Vernalis Design Platform (VDP) with the onc